Angion Biomedica Exclusively In-licenses Aldosterone Synthase Inhibitors from ElexoPharm GmbH Complementing its Ongoing Program in Chronic Kidney Disease

UNIONDALE, N.Y.–(BUSINESS WIRE)– Angion Biomedica Corp. announced today that it has signed an exclusive
license with ElexoPharm GmbH of Saarbrücken, Germany, for compounds that
target aldosterone synthase (CYP11B2), a cytochrome P450 enzyme involved
in the generation of aldosterone. Reducing aldosterone levels may be an
effective approach to treating chronic kidney disease, heart failure,
hypertension and fibrosis. The exclusive license agreement complements
Angion’s ongoing R&D program for this target pursuant to an NIDDK/NIH
grant. “The novel ElexoPharm portfolio of compounds provides for a
valuable source of new chemical entities in order to help Angion advance
its programs in chronic kidney disease (CKD)”, said Itzhak D. Goldberg,
M.D., Angion’s CEO.

ElexoPharm was founded in 2005 as a spin-off of the Saarland University
in Germany. ElexoPharm obtained its aldosterone synthase inhibitors from
the lab of Professor Rolf Hartmann, a world-renowned expert in this
field. Dr. Hartmann’s team identified novel classes of highly selective
aldosterone synthase inhibitors (CYP11B2) that spare the closely related
CYP11B1 target. “We are greatly pleased to have a close relationship
with Angion in order to facilitate the advancement of potent compounds
into the clinic for the treatment of CKD. Chronic renal disease affects
an enormous patient population, a condition for which there is currently
no effective treatment.” said Professor Hartmann.

“This license agreement and promising collaboration with Dr. Hartmann’s
outstanding team is consistent with Angion’s mission to develop new
therapeutics to address the full spectrum of renal diseases, which is
estimated to affect one in ten Americans” said Dr. Goldberg.

About Angion Biomedica Corp.

Angion Biomedica Corp. is a biopharmaceutical company established in
1998 to discover and develop novel therapeutic agents to treat patients
who experience acute and chronic organ disorders and diseases. Angion is
currently conducting clinical studies in renal transplantation and acute
kidney injury utilizing its proprietary therapeutic BB3 and has
additional preclinical programs for chronic renal diseases. For further
information, please visit www.angion.com,
or contact us at mail@angion.com.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170622005116/en/